Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | PLK1 | P53350 | 3/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PRMT7 | Q9NVM4 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5619992 | 0.87 | RAF1 (0.52) | MAPTLMNAPLK1RAF1BRAF | |
| SCHEMBL5621060 | 0.85 | MAPT (0.45) | MAPTHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL5619495 | 0.84 | MAPT (0.42) | MAPTHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL5620937 | 0.84 | MAPT (0.43) | MAPTHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL5619813 | 0.84 | BRAF (0.50) | MAPTLMNAPLK1BRAFRXFP1 | |
| SCHEMBL5619503 | 0.84 | PLK1 (0.46) | MAPTPLK1BRAFPRMT7 | |
| SCHEMBL5620338 | 0.83 | MAPT (0.43) | MAPTHDAC3HDAC1HDAC7HDAC8 | |
| SCHEMBL6287805 | 0.82 | PLK1 (0.45) | MAPTPLK1TP53SMN1; SMN2 | |
| SCHEMBL6291417 | 0.82 | PLK1 (0.45) | MAPTPLK1TP53PRMT7 | |
| SCHEMBL6291820 | 0.82 | TP53 (0.45) | LMNAPLK1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202243-B2 | Substituted imidazotriazines | BAYER HEALTHCARE AG (DE) | 2007-04-10 | — | — | US | disclosed |
| US-20060166993-A1 | Substituted imidazotriazines | BAYER HEALTHCARE AG (DE) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166993-A1 | Substituted imidazotriazines | SNCA, PARK7, TPMT | MAPT 164/4885HDAC3 1565/4885HDAC1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.